Blueprint Medicines Quick Ratio (BPMC) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Blueprint Medicines Corporation  (NASDAQ: BPMC)

Blueprint Medicines's Quick Ratio

BPMC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 2.3 a new company low.

Within Major Pharmaceutical Preparations industry 273 other companies have achieved higher Quick Ratio than Blueprint Medicines in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 268 to 982.

Explain Quick Ratio?
How much Cash & cash equivalents BPMC´s has?
What are BPMC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BPMC Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change 21.29 % 21.34 % 30.54 % 44.24 % 19.64 %
Y / Y Cash & cash equivalent Change -11.06 % -13.39 % 2.97 % 5.67 % -21.2 %
Quick Ratio MRQ 2.3 2.36 2.85 3.13 3.14
BPMC's Total Ranking # 982 # 268 # 683 # 500 # 516
Seq. Current Liabilities Change -3.92 % 1.22 % 5.68 % 18.01 % -3.87 %
Seq. Cash & cash equivalent Change -6.38 % -16.17 % -3.85 % 17.86 % -8.83 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 274
Healthcare Sector # 471
Overall Market # 982


Quick Ratio Statistics
High Average Low
15.7 6.77 2.3
(Dec 31 2017)   (Mar 31 2025)




Financial Statements
Blueprint Medicines's Current Liabilities $ 251 Millions Visit BPMC's Balance sheet
Blueprint Medicines's Cash & cash equivalent $ 576 Millions Visit BPMC's Balance sheet
Source of BPMC's Sales Visit BPMC's Sales by Geography


Cumulative Blueprint Medicines's Quick Ratio

BPMC's Quick Ratio for the trailling 12 Months

BPMC Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 28.54 % 28.49 % 27.78 % 23.16 % 14.16 %
Y / Y Cash & cash equivalent TTM Growth -3.75 % -6.98 % -10.82 % -21.83 % -25.63 %
Quick Ratio TTM 2.66 2.85 3.09 3.29 3.55
Total Ranking TTM # 3693 # 1321 # 3175 # 2617 # 422
Seq. Current Liabilities TTM Growth 4.54 % 4.97 % 6.99 % 9.49 % 4.5 %
Seq. Cash & cash equivalent TTM Growth -2.6 % -3.33 % 0.75 % 1.47 % -5.87 %

Quick ratio ranking by company, industry and sector >> Back to BPMC Financial Strength Comparisons >> Go to Compare BPMC Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2025 to $250.58 millions, cumulative Quick Ratio decreased to 2.66 below the Blueprint Medicines Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 478 other companies have achieved higher Quick Ratio than Blueprint Medicines. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 1321 to 3693.

Explain Quick Ratio?
How much Cash & cash equivalents BPMC´s has?
What are BPMC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 479
Healthcare Sector # 969
Within the Market # 3693


trailing twelve months Quick Ratio Statistics
High Average Low
8.76 2.76 0.34
(Dec 31 2015)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Cybin Inc   6.30 $ 103.427  Millions$ 16.406  Millions
Alzamend Neuro Inc   6.22 $ 3.949  Millions$ 0.635  Millions
Amarin Corp Plcuk  6.18 $ 282.087  Millions$ 45.661  Millions
Tango Therapeutics Inc   6.03 $ 216.724  Millions$ 35.917  Millions
Oramed Pharmaceuticals Inc  5.72 $ 30.396  Millions$ 5.311  Millions
Puretech Health Plc  5.59 $ 258.842  Millions$ 46.309  Millions
Marker Therapeutics inc   5.47 $ 13.693  Millions$ 2.501  Millions
Syndax Pharmaceuticals Inc   5.46 $ 516.313  Millions$ 94.551  Millions
Lava Therapeutics Nv  5.46 $ 106.274  Millions$ 19.468  Millions
Nucana Plc  5.43 $ 34.978  Millions$ 6.445  Millions
Ovid Therapeutics Inc   5.41 $ 42.996  Millions$ 7.947  Millions
Igm Biosciences Inc   5.39 $ 152.112  Millions$ 28.198  Millions
Gossamer Bio Inc   5.35 $ 257.934  Millions$ 48.223  Millions
Immutep Limited  5.28 $ 44.307  Millions$ 8.386  Millions
Longeveron Inc   5.26 $ 14.327  Millions$ 2.724  Millions
Alx Oncology Holdings Inc  5.22 $ 97.831  Millions$ 18.742  Millions
Bio Green Med Solution Inc   5.20 $ 3.450  Millions$ 0.663  Millions
Catalyst Pharmaceuticals Inc   5.20 $ 580.656  Millions$ 111.649  Millions
Arcus Biosciences Inc   5.19 $ 997.000  Millions$ 192.000  Millions
Relmada Therapeutics Inc  5.17 $ 27.061  Millions$ 5.231  Millions
Vireo Growth Inc.  5.15 $ 86.261  Millions$ 16.738  Millions
Forte Biosciences Inc   5.08 $ 45.856  Millions$ 9.032  Millions
Madrigal Pharmaceuticals Inc   5.07 $ 843.068  Millions$ 166.221  Millions
Prelude Therapeutics Inc  5.01 $ 99.074  Millions$ 19.787  Millions
Cogent Biosciences Inc   4.98 $ 245.661  Millions$ 49.318  Millions
Aldeyra Therapeutics Inc   4.94 $ 39.707  Millions$ 8.031  Millions
Hepion Pharmaceuticals Inc   4.90 $ 4.586  Millions$ 0.936  Millions
Silo Pharma Inc  4.90 $ 5.451  Millions$ 1.113  Millions
Aclaris Therapeutics Inc   4.90 $ 105.314  Millions$ 21.514  Millions
Pepgen Inc   4.79 $ 97.781  Millions$ 20.431  Millions

Date modified: 2026-09-08T16:52:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.